Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 344

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 344
---
 period. The calculation and assessment of the Company’s income tax exposures generally involve the uncertainties in the application of complex tax laws and regulations for US federal and state jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation, on the basis of the technical merits. As of December 31, 2024, the Company has not recorded any liabilities or interest and penalties related to uncertain tax positions in its financial statements. The Company recognizes accrued interest and penalties, if any, related to uncertain tax positions in tax expense in its financial statements. 13. Net Loss Per Share Basis and diluted net loss per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):

| ​                                                                         
 ​                                                                         | ​ 
 ​ | ​ 
 ​ | For the Year EndedDecember 31, 
 2024                           |   |            |   | ​ | ​ | 2023 |   |            |   | ​ 
 ​ |
|:--------------------------------------------------------------------------|:--|:--|:-------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Numerator:                                                                | ​ | ​ | ​                              | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Net loss attributable to common stockholders                              | ​ | ​ | ​                              | $ |    -29,397 | ​ | ​ | ​ | ​    | $ |    -17,347 | ​ | ​ |
| Denominator:                                                              | ​ | ​ | ​                              | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Weighted-average common shares outstanding, basic and diluted             | ​ | ​ | ​                              | ​ | 19,193,932 | ​ | ​ | ​ | ​    | ​ | 19,134,096 | ​ | ​ |
| Net loss per share attributable to common stockholders, basic and diluted | ​ | ​ | ​                              | $ |      -1.53 | ​ | ​ | ​ | ​    | $ |      -0.91 | ​ | ​ |

The Company’s potentially dilutive securities, which include stock options to purchase common stock and Preferred Stock, have been excluded from the computation of diluted net loss per share